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Abstract 
 
Malaria is one of the most important parasitic infectious diseases in terms 
of human and economical losses in developing countries. This disease is 
caused by Plasmodium and is transmitted to the vertebrate host by Anopheles 
mosquitoes. During malaria infection, Plasmodium parasites infect first 
hepatocytes and after the erythrocytes, here being responsible for serious 
pathological complications and some times to death. These two obligatory 
parasite developmental stages give to scientists two different approaches to 
fight malaria. The first, in the liver, preventing malarial disease associated 
symptoms and the second in the blood, to attenuating exacerbated clinical 
complications. 
Vitamin D, and particularly its active metabolite, 1,25α(OH)2D3, have 
been showed to be a potent immunoregulator. 1,25α(OH)2D3 can tune the 
immune system towards an anti-inflammatory state. Paradoxically, vitamin D is 
also associated with the production of antimicrobial peptides by the innate 
immune system.  
 In the present work we decided to take advantage of the particular 
immunoregulatory properties of 1,25α(OH)2D3 to study a potential antimicrobial 
effect in the Plasmodium Berghei liver stage and a potential anti-inflammatory 
effect in a cerebral malaria rodent model. 
 In the P. berghei liver stage infection our results show a in vitro reduction 
in the of infection of 1,25α(OH)2D3 treated human Huh7 and mouse Hepa1-6 
hepatoma cell lines by flow cytometry. In vivo, no differences were observed 
between 1,25α(OH)2D3 treated and untreated infected C57/Bl6 mice livers. 
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However, lower doses of 1,25α(OH)2D3 tend to reduced infection whether 
higher doses show the opposite tendency. 
 1,25α(OH)2D3 had no effect in the outcome of cerebral malaria in a 
murine cerebral malaria model. 
 In conclusion, 1,25α(OH)2D3 might have a potential antimicrobial effect 
in P. berghei liver stage. However, further studies should be made. 
 
Keywords: 
Malaria, Plasmodium, vitamin D, liver stage, cerebral malaria 
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Resumo 
 
A Malária é uma das mais importantes doenças infecciosas no que respeita a 
perdas humanas e económicas nos paises em vias de desenvolvimento. Esta 
doença é causada pelo Plasmodium e é transmitida ao hospedeiro vertebrado 
por mosquitos Anopheles. Estes parasitas, no hospedeiro vertebrado, infectam 
primeiro hepatocitos e seguidamente os eritrocitos, fase responsavel por 
complicações patologica séria que levam por vezes à morte. Estas duas fases 
de desenvolvimento necessárias ao parasita dão aos cientistas duas 
aboradagens deiferentes para combater a malaria. A primeira, no fígado, 
prevenindo os sintomas associados a esta doença e a seguinda, no sangue, 
atenuando as complicações clinicas. 
 A vitamina D, e em particular a sua forma activa, 1,25α(OH)2D3, são 
potentes reguladores do sistema imune. 1,25α(OH)2D3 pode modular o 
sistema imune para um estado anti-inflamatório. Paradoxalmente, a vitamina D 
está também associada com a produção de péptidos antimicrobianos pelo 
sistema imune. 
 No presente trabalho decidimos tirar partido das propriedades imuno-
regulatorias de 1,25α(OH)2D3 e estudar tanto potenciais efeitos 
antimicrobianos na fase hepática como potenciais efeitos anti-inflamatórios na 
fase sanguinea da infecção pelo Plasmodium Berghei tendo por modelo 
roedores. 
 Durante a fase hepatica da infecção do P. Berghei os nossos resultados 
mostram uma redução in vitro da infecção de linhas celulares de hepatoma de 
ratinho (Hepa1-6) e humano (Huh7), quando tratadas com 1,25α(OH)2D3 por 
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citometria de fluxo. In vivo, não foram observadas diferenças entre a infecção 
de figados de ratinhos C57/Bl6 tratados ou não com 1,25α(OH)2D3. Contudo, 
ratinhos sugeitos a doses reduzidas de 1,25α(OH)2D3 mostraram uma 
tendência para ter uma nenor infecção, enquanto doses mais altas mostraram 
uma tendência inversa. 
 1,25α(OH)2D3  não teve qualquer efeito no resultado final no modelo de 
malaria cerebral. 
 Em conclusão, 1,25α(OH)2D3  poderá ter um efeito antimicrobiano na 
fase hepática do P. Berghei. Contudo, deverão ser efectuados mais estudos.  
 
 
Palavras chave: 
Malaria, Plasmodium, Vitamina D, fase hepática, malária cerebral 
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1. Introduction and Objectives 
1.1. The Malaria Burden 
 
Malaria infection has strained the biological and cultural resources of 
human populations since ancient times, in an evolutionary associantion 
between host and parasite 23,68,99. The advent of agriculture was critical in 
establishing malaria infection in human population. Animal and plant 
domestication increased population size and an increased population density 
was able to support malaria propagation. Moreover, agriculture led to forest 
clearing and related environmental modifications that favoured breeding of 
malaria vector 43,45.  
 Human efforts to control malaria have markedly restricted its distribution 
during the 20th century 37. The global program of malaria eradication, 
coordinated and supported by the World Health Organization (WHO) started in 
1957, has been successful in most countries in the temperate climate zones of 
the globe. However, by the end of the 1960s it became evident that technical 
problems, such as resistance of mosquito vectors to insecticides and resistance 
of malaria parasites to drugs, presented serious obstacles to the pursuit of 
eradication programs in many tropical countries 4,8. 
The malaria situation deteriorated during the 90´s 37. Today malaria is 
one of the most important infectious diseases to humankind. Every year this 
parasitic disease affects 300-500 million people and causes 1-3 million deaths 
worldwide 84. It is a public health problem that affects around 40% of the world 
population. Ninety percent of malaria cases occur in the sub-Saharian Africa. 
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Mortality due to malaria is especially high among children under 5 years of age 
and pregnant women 33,37. Malaria represents a huge drawback to the 
development of the affected countries, both economically and socially, in a 
vicious cycle of poverty and disease 84.  
In 1998, World Health Organization (WHO) launched an international 
partnership, the Roll Back Malaria (RBM), whose goal is to attain a 50% 
reduction of the malaria burden based in a transversal approach to fight malaria 
by sustained country development 71. Although very naïve in their objectives, 
the RBM brought to discussion the world malaria burden and mobilized a huge 
effort to fight this disease. 
  
1.2. Plasmodium life cycle 
 
Plasmodium (P.), the malaria parasite exhibits a extremely complex life cycle 
(Fig. 1) involving two hosts, an insect vector, the female Anopheles mosquito, 
and a vertebrate host. This parasitic protozoan infects a wide range of 
vertebrate hosts including reptiles, birds, rodents, and primates and humans. 
Four Plasmodium species infect humans: P. falciparum, P. vivax, P. ovale and 
P. malariae. P. falciparum is by far the deadliest of the four and is responsible 
for most of the mortality and morbidity associated with malaria. All four species 
exhibit a similar life cycle with only minor variations 3,98.  
When a female Anopheles mosquito probes the human skin to obtain a 
blood meal, it injects saliva mixed with anticoagulants. If the mosquito is 
infected with Plasmodium, it will also inject an estimate average of around 15 
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sporozoites into the skin 59,81.  Sporozoites glide through the skin and are 
carried by the blood stream, rapidly reaching the liver sinusoids 5,26,78. After 
being sequestered in the sinusoids, sporozoites reach their initial site of 
multiplication in the mammalian host, the hepatocytes, by passing through 
Kupffer cells 77. Plasmodium parasites traverse several hepatocytes before 
invading a final cell. This traversing behaviour increases the susceptibility of 
host hepatocytes and activates the parasite, promoting its entry into a final 
hepatocyte, in which a parasitophorous vacuole (PV) is formed  64,66.  
After the final invasion, each Plasmodium sporozoite develops and 
undergoes an asexual replication known as exoerythrocytic schizogony within 
the hepatocyte 29, generating thousands of new parasites (merozoites). P. vivax 
and P. ovale can go through a dorment period in the liver, forming so-called 
hypnozoites 16. After full development, parasite-filed vesicles (merosomes) bud 
from the infected hepatocytes which transport mature merozoites to the blood 
stream 89. The Plasmodium liver stage is the first obligatory step and is clinically 
silent. 
Symptomatic disease is caused by merozoites that proliferate during the 
erythrocytic stage of the life cycle. The erythrocytic stage begins when 
merozoites emerge from the liver and invade erythrocytes. Each merozoite 
develops sequentially into a ring form, a trophozoite, and a schizont in an 
enormous numerical expansion through many cycles of mitotic replication. 
Schizont-infected erythrocytes rupture and release merozoites, which invade 
other erythrocytes 35.  
As an alternative to the asexual replicative cycle, the parasite can 
differentiate into sexual forms known as macro- or microgametocytes 3,97. When 
  
16 
the mosquito takes up an infected blood meal that contains sexual stages, 
microgametes exflagellate within minutes and fuse with a macrogamete to form 
a diploid zygote. The zygote transforms into a motile ookinete that traverse 
epithelial gut cells, encounters the basal lamina where it arrests and transforms 
into an oocyst. The oocyst undergoes several mitotic divisions and forms 
sporoblasts. Once formed, sporozoites actively move through the mosquito 
haemolymph to the salivary glands and start to acumulate in the salivary duct 57. 
The cycle is complete when the infected mosquito bites another host. 
 
 
 
1. Infected Anopheles female
transfer the sporozoites to 
the human host during a 
blood meal
2. The circulatory system 
transports the sporozoites 
to the liver. In the liver they
migrate through several 
hepatocytes before invading
a final one here they multiply.
3. Merozoites bud to the 
blood stream and infect 
erythrocytes.
4. Within the erythrocytes the 
parasites cyclically invade 
multiply, mature, are released
and infect new erythroytes
5. During the erythrocytic stage
some parasites diferentiate 
into gametocytes
6. Within the mosquito, parasite
gametes form a zygote that
develops into sporozoite and
glide to the mosquito salivary
glands
7. The Plasmodium life cycle
closes when the infected
female byte another human 
host
 
 
Figure 1.1. The Plasmodium life Cycle 
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1.3. Malaria pathology 
 
Symptoms associated with malaria are restricted to the erythrocytic stage 
of the Plasmodium life cycle in the vertebrate host. In humans, these symptoms 
display a large spectrum of intensity ranging from slight headache or mild fever 
to extremely severe life-threatening complications such as metabolic acidosis, 
cerebral malaria (CM) and severe malarial anaemia 61,85. The most severe 
pathologies are observed in non-immune individuals such as children in 
endemic areas, individuals living in areas of episodic transmission or migrants 
from non-endemic areas 101. The development of severe malaria probably 
results from a combination of parasite-specific factors, such as adhesion and 
sequestration in the vasculature and the release of bioactive molecules, 
together with host inflammatory responses 52,76. Traditionally, approaches to 
understanding pathogenesis have involved clinical studies in humans, 
experimental infections in animal models and in vitro modelling of pathogenic 
processes 52.  
The observation of large numbers of parasites accumulated in specific 
organs, such as the brain and the placenta, associated with adverse clinical 
outcomes, suggests that organ-specific accumulation of parasites is important 
in the pathogenesis of malarial disease. As circulating parasites mature, 
antigens expressed on the erythrocyte surface enable adhesion to endothelial 
cells and non-infected erythrocytes, forming rosettes and sequester in vascular 
beds. This adhesion phenotype, although detrimental to the host, seems to be 
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adaptive to the parasite since erythrocytes with mature parasites are 
sequestered from peripheral circulation and, thus, protected from spleen 
clearance 6,20.  
Toll like receptors (TLR) are responsible for the recognition of parasite 
molecules by innate immune system. Their activation in endothelial, 
macrophages and dendritic cells induces widespread expression Th1 pro-
inflammatory cytokines such as Tumour necrosis factor (TNF) and Interferon γ 
(IFN- γ) 31,76. The Th1 responses are important for the host to kill the parasite, 
however, in non immune individuals a cytokine storm is initiated with an 
unbalance between Th1 and Th2 immune responses. 
 
1.3.1. Cerebral malaria 
 
CM is a major life-threatening complication of Plasmodium infection 
which affects mainly children between 2-6 years old. CM pathology seem to 
include abnormally high production of Th1 cell-derived cytokines such as tumor 
necrosis factor (TNF)-α and IFN-γ induced by infected erythrocytes 15,31,32. 
These cytokines may play an important role in causing certain pathological 
changes, by up-regulating the expression of cell surface markers like CD36, 
ICAM-1, VCAM-1 and chondroitin sulfate A, thus leading to the sequestration of 
infected erythrocytes, leukocytes and monocytes in the cerebral capillaries. This 
accumulation induces flow perturbations that led to obstruction and hypoxia 76. 
Endothelial damage of brain microvasculature induce changes in the 
blood brain barrier exposing the brain parenchyma to cytokines and parasite 
antigens, activating the microglia and damaging astrocytes 44,58. 
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1.3.2. Severe malaria anaemia 
 
Severe malarial anaemia is seen most frequently in areas of very high 
malaria transmission and most commonly in young children and pregnant 
women 12. 
Anaemia results from the destruction of both infected and non-infected 
red blood cells and the decrease production of these cells, mainly due to an 
inadequate erythropoietic response of the bone marrow 60,61,97. The spleen 
plays a major role in removing parasitized and non-parasitized erythrocytes 
from circulation. In fact, this clearance was observed to be increased in patients 
with splenomegaly 61. Studies on bone marrow indicated a depression and a 
defective erythropoiesis during malaria infection 60,97. The removal of non-
infected red blood cells has been proposed as the major mechanism leading to 
persistence and worsening of anaemia following parasitaemia clearance. This 
could explain the lack of correlation between the parasitaemia level and 
anaemia observed in some studies that reported cases of patients with severe 
anaemia and low parasitaemias 45,61,68.  
 
1.4. Host-targeted antimalaria drugs 
 
The alarming increase in P. falciparum resistance to commonly used 
anti-malarial drugs represents a major public health threat. The current most 
important strategy used to fight resistance is the use of drug combinations such 
as arteminisin-based combination therapy 70. This strategy may delay the future 
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emergence of resistant strains but has limited application and do not solve the 
problem of existing antimalarial drug resistance with the addicional drawback of 
higher cost of the combination. 
Most antimalarial drugs target Plasmodium. However, P. falciparum is a 
highly variable parasite with immense recombination abilities. Recently, 
researchers are focusing on the modulation of host pathways as a different 
approach to a therapeutic strategy to fight malaria . Furthemore, resistance is 
less likely to occur if the targeted host component remains outside the 
microorganism 17.  
Host molecules are being studied as potential targets to fight 
Plasmodium infection. Liver molecules are potential prophylactic targets 17. 
Promising results have been achieved with the use of tyrosine kinase inhibitors 
to target Hepatocyte Growth Factor (HGF) and its receptor c-MET which impairs 
Plasmodium liver development 11,17. Harrison and co-workers, blocked invasion 
and development of Plasmodium erythrocytaic stages by inhibiting host 
erythrocyte Cs signalling 36,69. Both these host molecules are promising 
antimalarial drug target candidates.  
 
1.5. Vitamin D 
 
Vitamin D is mainly produced by the skin 42. This steroid hormone serves as a 
chemical messenger that triggers biological responses in many target tissues 
with different physiological actions including maintenance of calcium 
homeostasis, effects on the immune, cell proliferation and differentiation. The 
importance of this vitamin in human heath was first described in rickets almost a 
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hundred years ago 38. In the last years, vitamin D has emerged as a promising 
drug against autoimmune diseases, cancer and as an antimicrobial agent 
24,39,51
. Vitamin D deficiency is associated with higher susceptibility to infection. 
 
1.6. Vitamin D metabolism and physiology 
 
 The metabolism of vitamin D is well known. During sun exposure, UVB 
radiation is absorbed by the skin of 7-dehydrocholesterol resulting in the 
formation of Vitamin D3 41. Alternatively vitamin D, in the form of either vitamin 
D2 or D3 can be derived from dietary sources 30. Vitamin D3 is then transported 
in the blood by  the vitamin D binding protein (DBP) to the liver  where it is 
hydroxylated at C-25 by 1α-hydroxylase resulting in the formation of 25-
dihydroxyvitamin D3 (25(OH)D3) 13. 25(OH)D3 is transported by DBP to the 
kidney and hydroxylated at the 1α position by 25-dihydroxyvitamin 1 α-
hidroxylase, resulting in the formation of the active form of vitamin D 13,40 . 
 The active form of vitamin D has different target tissues where it can 
modulate a wide range of physiological actions (Table 1.).  
The high potency of 1,25α(OH)2D3 in elevating serum calcium and 
phosphate levels requires its circulating levels to be tightly regulated. Control of 
serum 1,25α(OH)2D3 usually involves reciprocal changes in the rates of 
synthesis and degradation. Hypocalcemia increases serum 1,25α(OH)2D3 
levels by stimulation of the kidney 25-dihydroxyvitamin 1α-hydroxylase, 
whereas hypercalcemia depresses α-hydroxylase activity and increases 24-
hydroxylase activity, the 24-hydroxylase is ubiquitously present in vitamin D 
target tissues, attenuating the response to the vitamin D hormone, and reducing 
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the levels of 1,25α(OH)2D3. Parathyroidectomy severely blunts the induction of 
the renal 1-hydroxylase by hypocalcemia. Finally, calcium can, by itself, directly 
suppress 1α-hydroxylase activity and mRNA levels 7. 
 
Table 1. 1,25α(OH)2D3 actions in classical and nonclassical target tissues 9 
  Tissue Cell type Action 
Classic    
 Intestine Epithelial Enhancement of calcium and phosphate absortion 
 Bone Osteoblast Enhance of bone matrix protein synthesis, bone 
      mineralization, and synthesis of mediators of osteo- 
  Osteoclast    clastogenesis and osteoclastic activity 
   Enhancement of bone resorption 
 Kidney Epithelial (proximal and distal) Inhibition of 1,25(OH)2D3 synthesis and induction of 
      24-hydroxylase 
   Enhancement of calcium and phosphate reabsortion 
 Parathiroid gland Chief Inhibition of  cell growth and PHT synthesis 
Nonclassic    
 Hematopoetic tissues Myeloid cell precursors Antiproliferative, prodiferentiating 
  Colony forming units Prodiferentiating 
 Immune System Monocyte/macrophages Enhancement of immune function to control viral and 
      bacterial infections and tumour growth 
  Lynphocyte Immunosuppression 
 Skin Keratinocytes, fibroblasts, hair folicule, Langerham Antiproliferative, prodiferentiating 
     cells, melanocytes  
 Muscle Smoth muscle cell, myoblast Antiproliferative, prodiferentiating 
 Heart Cardiac muscle cell Antiproliferative, prodiferentiating 
  Atrial myocytes Inhibition of antinatriuretic factor synthesis 
 Pancreas β-cells Enhancement of insulin synthesis and secretion 
 Cancer cells Melanoma, breast carcinoma, leukemia, osteosarcoma, Antiproliferative, prodiferentiating 
     fbrosarcoma, pituitary medullary thyroid carcinoma,  
  adenoma, neuroblastoma, pancreatic adenocarcinoma,  
  bladder, cervical, prostate and colon carcinomas  
 Adrenal gland Medullary cells Control of catecolamine metabolism 
 Brain Hypocampus/selected neurons Neuronal regeneration, enhacement of nerve growth 
      factor and neurotrophin synthesis, control of sphyn- 
      gomyelin cycle 
 Cartilage Chondrocyte Antiproliferative, prodiferentiating 
 Female reproductive Myometrial and endometrial cells Antiproliferative, prodiferentiating 
 Liver Parenchymal cell (fetal, adult) Enhancement of liver regeneration, control of glycogen 
      and transferrin synthesis 
 Lung Fetal pneumocytes Enhancement of maturation, phospholipid synthesis 
      and surfactant release 
  Adult pnemocytes Cell growth 
 Male reproductive organs Sertoli/semminiferus tubule Enhancement of Sertoli cell fuction and spermatogen- 
      Esis 
 Pituitary production Somatomammotroph Control of T3-induced growth hormone, prolactin and 
      Tyrotrophyn 
  Thyroid Follicular cells (C cells) Inhibition of cell function and calcitonin synthesis 
 1,25(OH)2D3. 1,25-dihydroxyvitamin D3: PHT. Parathyroid hormone: T3. triiodothyronine 
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1.7. Molecular actions of Vitamin D  
 
Most of the biological actions of 1,25α(OH)2D3 are mediated by binding to 
a high-affinity nuclear receptor, Vitamin D Receptor (VDR) that acts as a ligand-
activated transcription factor 19,50,. Nuclear receptors are ligand-activated 
regulators of gene transcription with a conserved domain structure 74. The 
highly conserved DNA-binding domain (DBD) contains two zinc fingers that 
form a single structural domain containing a α-helical reading head that controls 
specific DNA sequence recognition. The VDR ligand-binding domain (LBD) not 
only binds ligand but also contains a ligand-regulated C-terminal AF-2 domain 
(activating function-2) that is essential for its capacity to activate transcription 82. 
Strong interactions between VDR and RXR LBDs are essential for ligand-
dependent dimerization and high-affinity DNA binding. Nuclear receptors 
regulate target gene transcription by ligand-controlled recruitment of several 
accessory proteins known collectively as coregulators. Coregulators are 
essential for the histone modifications, chromatin remodeling and recruitment of 
RNA polymerase and ancillary factors that are necessary for the initiation of 
transcription 22.  
Vitamin D response elements (VDREs) are composed of tandem motifs 
with the consensus PuG(G/T)TCA often arranged as direct repeats separated 
by three base pairs 50. 
 The active metabolite 1,25(OH)2D enters the cell and binds the vitamin 
D receptor (VDR). This complex forms a heterodimer with the retinoid receptor 
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and binds to a vitamin D responsive element on a responsive gene, such as 
that of osteocalcin, calcium binding protein or 24-hydroxylase. This is followed 
by transcription and translation, generating proteins such as the calcium binding 
protein or osteocalcin 39. The classic effect of 1,25(OH)2D on active calcium 
transport occurs in the intestinal cell. Like the other members of the steroid 
receptor family, the VDR acts as a ligand-activated transcription factor. The 
domains of the VDR involved in the major steps for VDR control of gene 
transcription are 50: 1) ligand binding, 2) heterodimerization with retinoid X 
receptor (RXR), 3) binding of the heterodimer to vitamin D response elements 
(VDREs) in the promoter of 1,25(OH)2D-responsive genes, and 4) recruitment of 
VDR-interacting nuclear proteins (coregulators) into the transcriptional pre-
initiation complex, which markedly enhance or suppress the rate of gene 
transcription by the VDR. 
1α,25(OH)2D3 is a conformationally flexible molecule and is known to 
stimulate a wide array of rapid responses (RR); some examples include the 
rapid intestinal absorption of calcium, secretion of insulin by pancreatic T3-cells, 
opening of voltage-gated Ca2+ and Cl- channels in osteoblasts, and the rapid 
migration of endothelial cells. One conformation of 1α,25(OH)2D3 is used for 
genomic responses, and an alternative one serves as an agonist of rapid 
responses. It is clear that VDR, DBP, and the receptor for 1α,25(OH)2D3-
mediated RR each have a characteristic ligand confromation. Binding of 
1α,25(OH)2D3 to the caveolae-associated VDR may result in the activation of 
one or more second messenger systems, including phospholipase C (PKC), 
protein kinase C, G protein-coupled receptors, or phosphatidylinositol-3-kinase 
(PI3K). There are a number of possible outcomes including opening of the 
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voltage-gated calcium or chloride channels or generation of the indicated 
second messengers. Some of these second messengers, particularly 
RAF/MAPK, may engage in cross-talk with the nucleus to modulate gene 
expression 73. 
 
1.8. Immunological effects of Vitamin D 
 
Vitamin D receptors have been found in most cells of the immune system 
and 1,25(OH)2D3 is a potent immune system modulator 56. There is 
considerable scientific evidence that 1,25(OH)2D has a variety of effects on 
immune system function that may enhance innate immunity and inhibit the 
development of autoimmunity 34,,55,94. 
 
1.8.1. Anti-inflammatory actions of Vitamin D 
 
An anti-inflammatory role for vitamin D has been recognised for some 
time and it has been specifically identified as exerting protection in conditions 
that are associated with polarization of T-cell responses to the Th1. 
1,25(OH)2D3 has been shown to reduce the inflammatory changes associated 
with delayed hypersensitivity, inflammatory bowel disease and experimental 
encephalomyelitis as well as with allograft survival 2,9. 
1,25(OH)2D3 promotes the differentiation of helper T cells from Th1 to 
Th2 reducing the production of interferon γ (IFN- γ), interleukin-2 (IL-2) and 
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tumour necrosis factor-α (TNF-α) 48. Th1 cell activation is essential for strong 
cell-mediated immune responses, including host responses to tumours and 
pathogens 1. By inhibiting IFN-γ transcription, the major positive feedback signal 
for antigen-presenting cells, 1,25(OH)2D3 prevents further antigen presentation 
to and recruitment of T lymphocytes 49. IL-2 is an autocrine growth factor for T 
lymphocytes and inhibition of its expression by 1,25(OH)2D3 prevents their 
further activation and proliferation. While inhibiting the synthesis of the Th1 
cytokines IL-2 and IFN-γ, and thus indirectly inducing CD4+ T lymphocytes to 
polarize towards a Th2 phenotype, increases the production of Th2 cytokines 
such as tumour growth factor (TGF) and interleukin 4 (IL-4) 9,49. 
As result of the anti-inflammatory properties of1,25(OH)2D3 and its 
analogues, these molecules became ackowledged as  immune suppressants 
2,21
. 
 
1.8.2. Vitamin D and infectious diseases 
 
Although, 1,25(OH)2D3 has anti-inflammatory properties, 1,25(OH)2D3 
has been shown to have no effect on the susceptibility of mice to infections with 
herpes simplex virus or Candida albicans with doses that had been shown 
previously to prolong allograft survival 10. Surprisingly, little is known about the 
effect of vitamin D status on the ability of the host to fight infections. One 
experiment in VDR KO mice showed that they mice exhibited increased 
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granulomatous inflammation (slightly more severe infection) during Schistosoma 
mansoni infection, compared with WT mice 28.  
1,25(OH)2D3 reduced inflammation and parasite load in experiments with 
Trypanosoma cruzi in mice 86 and inhibited in vivo and in vitro the intracellular 
growth of Toxoplasma gondii 70. In the 80’s, Vial and co-wprkers showed that P. 
falciparum growth is inhibited in the presence of vitamin D 95. 
The only example of an explored immune antimicrobial effect of 
1,25(OH)2D3 is with tuberculosis. In the pre-antibiotic era, vitamin D was used 
for treatment of tuberculosis 53. 1,25(OH)2D induces anti-mycobacterial activity 
in vitro in both monocytes and macrophages. Exogenous 1,25(OH)2D induces a 
superoxide burst and enhances phagolysosome fusion in M. tuberculosis-
infected macrophages. Both phenomena are mediated by phosphatidylinositol 
3-kinase, suggesting that this response is initiated by ligation of membrane 
vitamin D receptor (VDR) 54. 1,25(OH)2D3 also modulates immune responses 
by binding nuclear VDR and TLR activation  upregulates protective innate host 
responses, including induction of nitric oxide synthase and cathelicidin,  and 
down-regulates IFN γ gene expression 51. 
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1.9. Objectives  
 
 
The main aim of this project is to investigate the involvement of vitamin D 
during Plasmodium infection of a mammalian host. Specifically, we propose to 
answer the following questions: 
a) Is liver infection by sporozoites impaired by the active form of vitamin D? 
b) Will the anti-inflammatory properties of vitamin D interfere in the outcome 
of CM? 
 
To achieve our aims, both in vitro and in vivo models of malaria infection 
were used, a hepatoma cell line culture system and a rodent model of CM, 
respectively. This enabled exploring different biological approaches for 
addressing the effects of vitamin D in the modulation of Plasmodium infection. 
In view of the dual effects of vitamin D, both anti-inflammatory and antimicrobial, 
it can be expected that vitamin D may hold prophylactic/therapeutic potential 
against malaria infection. 
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2. Materials and Methods 
 
2.1. Cells 
 
Two hepatoma cell lines were used for in vitro experiments: HuH7 a 
human hepatoma cell line 72 and a mouse hepatoma cell line Hepa 1-6 (ATCC, 
CRL-1830) 18. Both cell lines are efficiently infected by rodent malaria parasites 
which are capable of undergoing complete development 67,87.  This was the in 
vitro model for malaria liver stage infection during the experimental studies. 
Hepatoma cells were maintained and kept in cell incubators at 37˚C with a 5%. 
Hepa1-6 cells were maintained in Dubelco’s MEM medium (DMEM, Invitrogen) 
supplemented with 10% heat inactivated Foetal Calf Serum 
(FCS)(Gibco/Invitrogen) and 1% Penicilin-Streptomycin (PS) (Gibco/Invitrogen). 
Huh7 were maintained in RPMI medium (RPMI 1640/Invitrogen) supplemented 
with 10% FCS (Gibco/Invitrogen), 1% PS, 1% Hepes (Gibco/Invitrogen) and 1% 
Non Essential Anino Acids (NEAA) (Gibco/Invitrogen). For Lentiviral production, 
HEK293T human embryonic kidney cells were maintained and kept in cell 
incubators at 37˚C with a 5%. Hepa1-6 cells were maintained in Dubelco’s MEM 
medium (DMEM, Invitrogen) supplemented with 10% heat inactivated Fetal Calf 
Serum (FCS) (Gibco/Invitrogen) and 1% Penicilin-Streptomycin (PS) 
(Gibco/Invitrogen). 
Cells were periodically tested for mycoplasma infections, as previously 
described 91. 
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2.2. Mice, mosquitos and parasites 
 
C57/BL6 mouse strains aged between 6-8 weeks were used as a 
cerebral malaria model 83 and were supplied by Instituto Gulbenkian de 
Ciência’s (IGC) animal house. Animals were bred, maintained and 
experimentally used in a pathogen-free animal facility. Mice were feed with RM3 
food  (SDS-England) with a vitamin D content of 4000UI/Kg. All animal care and 
procedures were in accordance with European regulations. 
Anopheles stephensi infected mosquitos were supplied by the University 
Medical Center St. Radbound (Nijmegen, The Netherlands) and our own 
insectarium and maintained under adequate controled conditions until being 
used. 
Plasmodium berghei ANKA sporozoites expressing GFP 25 were 
obtained from infected mosquitoes and were used either in vitro or in vivo 
experiments. Parasites were maintained by alternate cyclic passages in 
mosquitos and mice 92. 
 
 
2.3. Sporozoite isolation and purification 
 
Female Anopheles staphensi mosquitos were fed on infected 
Plasmodium berghei ANKA mice. Sporozoites were obtained by dissection from 
their salivary glands at days 18-21 post feeding. Dissections of mosquito 
salivary glands were performed in RPMI medium (Gibco, Invitrogen). The 
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glands were mechanically disrupted and homogenized to free the parasites. 
The debris were pelleted after spinning at 20g for 5 min at 4˚C. Sporozoites 
were then collected, counted and maintained on ice until use. The number of 
sporozoites per infected mosquito was determined using a hemacytometer 
(Newbauer chamber). 
 
2.4. Lentiviral production and cell transduction 
 
To knockdown the expression o the vitamin D receptor (VDR) an 
incompetent lentivirus was produced by transfection of a packaging cell line with 
the lentiviral genome split in different plasmids 63,75. Lentiviral particles were 
produced by cotransfection of pLKO.1 puro plasmid (Fig. 2.1.) with the 
packaging construct pCMV Delta 8.9, an envelope coding plasmid pCMV-VSV-
G. This method allow persistent expression of small RNA molecules that will 
target specific gene mRNA degradation, named RNA interference (RNAi); and 
resistance to puromycin to the transduced cells 88. 
In a 96 well plate, 2,6X104 HEKC 293T cells were seeded in a 96 well 
plate 24 hours before transfection. Transfection was performed by mixing 100 
ng of pCMV-VSV-G, 10ng pCMV Delta 8.9 and 10ng VDR-pLKO.1 or pLKO.1 
for controls (table 2.1.) plasmids and 0,6µL of Fugene 6 (Roche) with OptiMEM 
(Invitrogen) in a total volume of 50µl. After 30 min. of incubation the mixture was 
added to the 60%-80% confluent cells. Supernatants with lentiviral particles 
were collected every 8/16 hours for 48 hours and then aliquoted and stored in -
80˚C. 
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Figure 2.1. pLKO.1-puro vector. Description and features: cppt - Central 
polypurine tract; hPGK - Human phosphoglycerate kinase eukaryotic promoter; 
puroR - Puromycin resistance gene for mammalian selection; SIN/LTR - 3' self 
inactivating long terminal repeat; f1 ori - f1 origin of replication;  ampR - 
Ampicillin resistance gene for bacterial selection; pUC ori - pUC origin of 
replication; 5' LTR - 5' long terminal repeat; Psi - RNA packaging signal; RRE -
Rev response element.  
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Transduction of Huh7 cells were performed by seeding 24 hours before 
3x104 cells in 96 well plates. In the day of transduction, lentivirus aliquots were 
thawed in ice for 30 min. After collection of the cell media, 10µL of supernatant 
in 40µL of media and polybrene (Sigma) was added to the cells. Cells were 
then centrifuged at 2200 rpm, 37˚C for 90 min., after centrifugation, the mixture 
with the lentivirus was removed and fresh media was added to the cells. Cells 
were incubated in the cell incubator for 36hours at 37˚C with 5% CO2. 
Transduced cells were then selected by adding 12,5 µg/mL of puromycin 
(Sigma) for 36hours at 37˚C with 5% CO2. Cells were the expanded and used 
for Plasmodium infection assays. 
 
2.5. In vitro cell infections and treatment with1,5α-dihidroxivitamin D  
 
Three to one day before infection, 1,5x105 Huh7 cells or 2x105 Hepa1-6 
cells were seeded in 24 well plates with the cell line respective medium and 
different concentrations of 1,5α-dihidroxivitamin D (Sigma) for control DMSO 
(Sigma) was added and grow in the respective media. P. berghey sporozoites, 
were added to the Huh7 and Hepa1-6 cell, 3x104 and 5x104 respectively. Cells 
were centrifuged for 5 min. at 1800g and incubated at 37˚C with 5% CO2. After 
24 hours cells were washed processed either for immunochemistry, flow 
cytometry analysis or real-time PCR for quantification of P. berghei ANKA 
infection. 
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2.6. Immunochemestry 
 
For quantification of in vitro infection by immunochemestry, after 
incubation with P. berghei ANKA sporozoites cells were fixed with a 2% PFA for 
30 min. After fixation, cover slips containing infected cells were incubated with a 
protein blocking solution (3% Bovine Serum Albumin, 100mM Glycine, 10% 
FCS) to avoid unspecific reaction, containing 0.1% Saponin (Sigma) for 
permeabilization, for 30 minutes, rinsed twice shortly in PBS, and incubated 45 
minutes RT with a monoclonal antibody against anti HSP70 (also known as 
2E6, produced by a hybridoma cell line). After smooth rinsing of the coverslips 
to remove exceeding mAb, they were incubated with mAb Cy2 Alexa Fluor® 
488 for mice IgG (dilution 1:2000) for 45 minutes a room temperature. 
Following, removal of exceeding mAb. Then, the coverslips are mounted in 
glass slides, with a mounting medium, Mowiole and then observed in a 
Fluorescence Microscope. Infection rate was quantified by counting the total 
number of parasite infected cells per cover slip. 
 
2.7. Migration assay 
 
 Plasmodium migration assay was performed as describe elsewhere with 
some adaptations 65. Huh7 cells were seeded 24 hours before infection 75x103 
cells for each 24 well plate. Before adding 30X103 sporozoites cells were 
washed and was added 200µL of 50mg of Dextran (Sigma) diluted in media to 
the cells. During 2 hours the added sporozoites were allow to migrate through 
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the cells that able  Dextran dye to enter in the cells. Cells were then washed 
with PBS trypsinized, washed again by centrifugation, ressuspended in PBS. 
The percentage of Dextran positive cells were recorded by flow cytometry . 
 
2.8. Flow cytometry 
 
After incubation with P. berghei ANKA sporozoites cells were detached 
by trypsinization, washed and pelleted in a solution of 20% FCS and 
ressuspended in 10%FCS in PBS before flow cytometry analysis. Not infected 
cells were used has control. EEfs sizes was accessed by GFP intensity in GFP 
positive cells 79. 
In vivo peripheral blood was collected by tail bleeding and diluted in PBS 
with heparin (50U/mL). The percentage of GFP P. berghei infected cells was 
monitored over time from days 3 pos-infection until the end of the experiment. 
 
2.9. Quantitative Real-time PCR (qRT-PCR) 
 
After incubation with P. berghei ANKA sporozoites cell RNA was 
extracted using RNeasy Micro Kit (Qiagen) in vitro or RNeasy Mini Kit (Qiagen) 
for livers, using the supplier instructions. One microgram of RNA from each 
sample was then used to produce cDNA by reverse transcription using the First 
Strand cDNA Synthesis Kit (Roche). The synthetized cDNA was used to amplify 
P. berghei 18S rRNA or VDR mRNA and HPRT (Table 2.1.) using SYBRgreen 
(Power SYBRgreen, Applied Biosystems). Amplification was performed in 
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Corbertt RG6000 (Corbett Life Sciences). Control plasmids with standard 
concentrations of 18S rRNA gene, from 102 to 108 copies were used in the 
assay and were synthesized as described elsewhere. A similar qRT-PCR was 
performed for a house-keeping gene, Hypoxanthine Guanine 
Phosphoribosyltransferase (HPRT), for standardization of values obtained 
(Witney, 2001). For VDR gene serial dilutions were used to give a relative 
concentration curve. 
 
Table 2.1. Hairpin and primer sequences used for qRT-PCR and iRNA  
Name Sequence 
hVDR hp 1 
5' - CCGGCGAAGTGTTTGGCAATGAGATCTCGAGATCTCATTGCCAAACACTTCGTTTTT - 3' 
hVDR hp 2 5' - CCGGGTCATCATGTTGCGCTCCAATCTCGAGATTGGAGCGCAACATGATGACTTTTT - 3' 
hVDR hp 3 5' - CCGGCCTCCAGTTCGTGTGAATGATCTCGAGATCATTCACACGAACTGGAGGTTTTT - 3' 
hVDR hp 4 5' - CCGGCCCTGGAGACTTTGACCGGAACTCGAGTTCCGGTCAAAGTCTCCAGGGTTTTT - 3' 
hVDR hp 5 5' - CCGGCGCGTCAGTGACGTGACCAAACTCGAGTTTGGTCACGTCACTGACGCGTTTTT - 3' 
hHPRT For 5’ – TGC TCG AGA TGT GAT GAA GG – 3’ 
hHPRT Rev 5’ – TCC CCT GTT GAC TGG TCA TT – 3’ 
mHPRT For 5’ – GTA ATG ATC GTC GTC AAC GGG GGA – 3’ 
mHPRT Rev 5’ – CCA GCA AGC TTG CAA CCT TAA CCA – 3’ 
Pb 18S For 5’ – GGA GAT TGG TTT TGA CGT TTA TGT G – 3’ 
Pb 18S Rev 5’ – AAG CAT TAA ATA AAG CGA ATA CAT CCT TAC – 3’ 
mVDR For 5’ – CTC CTC GAT GCC CAC AAG ACC TAC G – 3’ 
mVDR Rev 5’ – GTG GGG CAG CAT GGA GAG CGG AGA CAG – 3’  
hVDR For 5’ – CCA GGA TAA GAT CCG GCT GG – 3’  
hVDR Rev 5’ – AAA GTA GCG AGA GGC ACC AA – 3’ 
h: human; m:mouse; VDR: Vitamin D Receptor; Pb: Plasmodium berghei; Rev: Reverse; For: Forward;  
 
 
2.10. In vivo liver infections 
 
Mice pretreated with 1,5α-dihydroxivitamin D or vegetal oil (Sigma) alone was 
infected with 2x104 sporozoites by intravenous injection. Livers were dissected 
40 hours post infection, and immediately suspended in 4 ml volume of 
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Denaturing Solution (4M Guanidium Thiocyanate, 25mM Sodium Citrate pH 7, 
and 0.5% N-Laurosyl-sarcosine) plus 0.1M β-mercaptoethanol, and stored at 
4ºC until homogenization. Livers were homogenized with a Tissue Tearer 
bladder. Liver homogenates were aliquoted (3×300µl per sacrificed animal) and 
stored at -80ºC (Witney, 2001). Liver homogenates were then used to quantify 
P. berghei liver infection by qRT-PCT (Section 2.8.) 
 
2.11. In vivo blood infections and disease assessment 
 
One mouse per experiment was infected with P. berghei infected blood from -
80˚C vials (passage mouse). When the mouse had a 1-10% parasitemia, it was 
sacrificed and blood collected by heart puncture. Blood was washed 3 times 
with PBS (centrifuging at 1699g at 4˚C for 3 min.), and then diluted in PBS to 
achieve 105 infected erythrocytes per 200µL. The mice for blood stage 
experiments were then infected with the diluted blood by intra peritoneal 
injection with a dose of 105 P. berghei infected erythrocytes. Parasitemias were 
monitored by flow cytometry as described above. Infected mice were monitored 
twice daily for clinical symptoms of CM including hemi- or paraplegia, head 
deviation, tendency to roll over on stimulation, ataxia and convulsions. 
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2.12. Statistical analysis 
 
Analyses were performed using the unpaired Student's t parametric test 
or analysis of variance (ANOVA) parametric tests. Normal distributions were 
confirmed using the Kolmogorov-Smirnov test. To make multiple comparisions 
versus control group was used the Holm-Sidak method. The tests were 
statistically significant when p≤0,05. Correlations were made using the 
Pearson’s correlation coefficient. 
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3. Results 
3.1. Liver stage 
3.1.1. Vitamin D effect in P. berghei in vitro infection 
 
To study the effect of the active form of vitamin D (1,5(OH)2D3) on hepatoma 
cell lines (Hepa1-6 and Huh7) we made a preliminary assay by treating Huh7 
with 10-6 of the tested drug against a solvent treated control for 48 hours. After 
24hours 20x103 sporozoites were added to cells. After another 24hours of 
incubation cells were fixed and stain agains P. berghey, cell actin and nucleus. 
Total EEFs were count by fluorescent microscopy (Fig. 3.1.1.). 
 
 
 
 
 
Figure 3.1.1. – Effect of 1,25(OH)2D3 on Plasmodium sporozoite infection 
of Huh7 cells. 10-6M of 1,25(OH)2D3 was added or with DMSO (control) to 
Huh7 cells. After 24 hours of incubation 20x103 sporozoites were added to 
cells. Infection was quantified 24 hours pos-infection by counting the total 
number of infected cells (EEFs) per well (average±stdev; t-test, p≤0,05). 
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The active form of vitamin D reduced the number of EEFs in comparison  to the 
control cells by around 35%.  
To address if the difference observed between treatments was 
associated with an effect during migration phase of the parasite a migration 
assay with dextran was performed (Fig. 3.1.2.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.2. – Quantification of dextran positive (transversed) cells in both 
control (DMSO) and 1,5(OH)2D3 treated cells and GFP positive cells 2 hours 
after adding 5x104 P. berghei sporozoites (average+stdev; t-test; p>0,05). 
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To address if this effect was cell line specific we used mouse Hepa1-6 cell line 
using the same protocol. Flow cytometry and quatitative real-time PCR (qRT-
PCR) was used to quantify P. berghei infection. 
 Both cell lines were susceptible to 1,25-(OH)2D3 with less infected cells. 
However Huh7 cells show a less striking effect in the percentage of infected 
cells. The same tendency was seen when the number of P. berghei copies 
versus HPRT was quantify but with no statistical differences (Fig. 3.1.3.).  
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Figure 3.1.3. – Quantification of P. berghei infection in mouse (Hepa1-6) 
and human (Huh7) hepatoma cell lines. Infection of 1,25-(OH)2D3 treated 
and untreated (control) cells was quantified 24 hours pos-infection by (A) 
flow cytometry and (B) qRT-PCR (average+stdev; t-test, * p≤0,05) 
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Parallel to the former experiment, Huh7 and Hepa1-6 hepatoma cells were 
treated with different concentration of 1,25-(OH)2D3 to see if the effect of the 
reduction in parasite number was dependent in drug concentration. However, 
real-time PCR didn’t show again any differences between control samples and 
samples with different concentration of 1,25-(OH)2D3 (Fig. 3.1.4.). 
A.
Huh7
Control 10-9M 10-7M 10-6M
0
10000
20000
30000
40000
50000
Pb
A/
hH
PR
T
 
B.
Hepa 1-6
Control 10-9M 10-7M 10-6M
0
100
200
300
400
Pb
A/
m
HP
RT
 
 
Figure 3.1.4. – Titration of 1,25-(OH)2D3 in Huh7 and Hepa1-6 hepatoma cells. 
Cells were treated with different drug concentrations. In both treated and 
untreated cells, infection was measured 24 hours pos-infection. The Y axis is in 
arbitrary units (mean±stdev) 
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 This difference between flow cytometry and real-time PCR could be 
explained if somehow the few number of the EEFs present in the 1,25-(OH)2D3 
treated samples had more parasites (and so, parasite DNA copies). Acessment 
of EEFs size by GFP intensity by flow cytometry analysis no differences were 
observed between the EEFs of treated and untreated samples (Fig. 3.1.5.) 
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Figure 3.1.5. EEFs size acessment by GFP intensity: A- Hepa1-6 hepatoma 
cells; B- Huh7 hepatoma cells. 
 
To study whether the knock down of the Vitamin D receptor influences 
the infection of P. berghei Huh7 cells were transduced with lentivirus this 
method allow persistent expression of interfering RNAs targeting the VDR 
mRNA leading to a knock down of this gene. Lentiviral transduction with the 
hairpins 1, 2, 3 and 4 reduced the percentage of infection compared with the 
control (ANOVA;Holm-SidaK; p≤0,05)  (Fig. 3.1.6). This result suggest an 
important role of VDR in P. berghei infection. However it was not possible to 
quantify the VDR knock down and this way correlate the differences in infection 
with the level of knock down. 
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Figure 3.1.6. Comparison between the percentage of P. berghei infection in 
different Huh7 hepatoma cell lines transduced with different VDR targeted 
hairpins (ANOVA; Holm-Sidak; p≤0,05)  
 
 
3.1.2. Effect of vitamin D in P. berghei liver infection 
In vivo, C57BL/6 were injected intra peritonially (IP) with 0,5µg/Kg on day 3 and 
1 before infection with 20x103 sporozoites intravenously (IV) by caudal vein. 
After 40 hours livers were collected and P. berghei infection by qRT-PCR. Mice 
treated with 1,25-(OH)2D3 show a tendency to have less DNA copies of P. 
berghei, this tendency is, however, not statistically significant different (t-test; 
p>0,05) between 1,25-(OH)2D3 treated and untreated mice (Fig. 3.1.6.). 
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A second experiment was made, this time using a higher dose (5µg/kg) 
delivered by gavage for longer alternate days, 15 days before infection. After 
infection livers were processed using the same methodology quantifying P. 
berghei infection and Vitamin D Receptor (VDR) both in treated and untreated 
mice (Fig. 3.1.7.A). Treated mice showed a tendency to have higher P. berghei 
DNA copy numbers, this tendency was not statistically significant (t-tet; p>0,05). 
However, the Vitamin D Receptor (VDR) expression was higher in 1,25-(OH)2D3 
pre treated mice livers (t-test, p≤0,05) (Fig. 3.7.B) showing that this dose of 
1,25-(OH)2D3  had an effect in VDR number in the mice’s livers.  Mice with 
higher expression of VDR had a positive correlation with higher number of P. 
berghei copies (Pearson correlation, r2=0,4337)(Fig. 3.1.7.C).  
Figure 3.1.6. – Quantification by qRT-PCR of P. berghei infection in livers 
of mice injected IP with 0,5µg/Kg or vehicle (control) of 1,25-(OH)2D3 on 
day 3 and 1 before infection. Infection was quantified 40 hours after 
infection. (average±stdev;n=5; t-test; p>0,05) 
Control 1,25 α -(OH)2D3
0
1000
2000
3000
4000
Pb
A/
m
HP
RT
  
48 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.7. – Effect of 1,25-(OH)2D3 in in vivo infection of P. berghei in livers 
of mice treated by gavage for 15 alternately with 5µg/kg (average+stdev;n=5) A; 
this dose raised the Vitamin D Receptor (VDR) numbers in treated mice 
(average+stdev;n=5;t-test; p<0,05) B; the increase of VDR copy number was 
correlated with P. berghei copy number (Pearson; r2=0,4337) C. 
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3.2. Blood stage 
 
3.2.1 Vitamin D effect in a Cerebral Malaria (CM) model 
 
To study the possible effect of Vitamin D (1,25-(OH)2D3) in a CM model 
C57/Bl6 mice were pre-treated different doses of 1,25-(OH)2D3 infected with 105 
P. berghei infected red blood cells by vein injection and parasitemia (Fig. 3.2.1.) 
and survival rates (Fig. 3.2.2.) were observed. 
The peripheral parasitemia of the three different mice groups was not 
different between the different treatment compared with the controls (t-test; 
p>0,05) and all mice died between day 7 and day 10 pos-infection with 
neurological symptoms including hemi- or paraplegia, head deviation, tendency 
to roll over on stimulation, ataxia and convulsions. These findings suggest us no 
influence of the administration of 1,25-(OH)2D3 in the peripheral blood 
parasitemias nor in the CM.  Again a more controlled designed experiment with 
a vitamin D depleted diet and monitoring the circulating titers of the vitamin D 
forms would give as a more conclusive result. 
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Figure 3.2.1. – Parasitemia of both 1,25-(OH)2D3  treated and untreated 
C57/Bl6 with different doses and routes of administration. Mice were injected IP 
with 105 P. berghei infected red blood cells, and parasitemia was monitored by 
flow cytometry from day 3 pos-infection until death. A. Mice treated with 
2,5µg/Kg of 1,25-(OH)2D3 or vehicle only (vegetal oil) administered by gavage; 
B. Mice treated with 2,5µg/Kg of 1,25-(OH)2D3 or vehicle only (vegetal oil) 
administered by intra peritoneal injection; C. Mice treated with 0,5µg/Kg of 1,25-
(OH)2D3 or vehicle only (vegetal oil) administered by intra peritoneal injection.  
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Figure 3.2.2. Comulative survival curves of both 1,25-(OH)2D3  treated and 
untreated C57/Bl6 with different doses and routes of administration. Mice were 
injected IP with 105 P. berghei infected red blood cells, survival and acute 
cerebral malaria syndromes was monitored. A. Mice treated with 2,5µg/Kg of 
1,25-(OH)2D3 or vehicle only (vegetal oil) administered by gavage; B. Mice 
treated with 2,5µg/Kg of 1,25-(OH)2D3 or vehicle only (vegetal oil) administered 
by intra peritoneal injection; C. Mice treated with 0,5µg/Kg of 1,25-(OH)2D3 or 
vehicle only (vegetal oil) administered by intra peritoneal injection.  
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4. Discussion 
 
 
Vitamin D has a well known role in the regulation of calcium 
homeostasis. More recently, vitamin D has become a hot topic in immune 
regulation. The vitamin D and particularly its active form 1α-25-dihydroxyvitamin 
D3, has showed anti-inflammatory and paradoxically antimicrobial properties. 
The innate immune responses provide a rapid host mechanism for defence 
against microbial pathogens. Activation of Toll-like receptors induces 
expression of antimicrobial peptides and this expression is directly link to 
vitamin D. 
In this study, we took advantage of the present knowledge of vitamin D 
as an immune modulator and proposed to study the effect of vitamin D in the 
outcome of the Plamodium berghei infection in both the liver stage and in the 
outcome of cerebral malaria in a murine model. 
 
4.1. Liver stage infection 
4.1.1. In vitro P. berghei infection 
 
A reduced number of infected hepatoma cells were observed in the 
presence of 1,25α-dihydroxyvitamin D (1,25α(OH)D3) by immunichemestry and 
flow cytometry. However, when the infection was quantified by qRT-PCR no 
differences was found. This could be possible if the drug reduce P. berghei 
invasion but promote intracellular development. No differences in EFF size was 
found to support this hypothesis. These differences might be due to some 
artefact associated by these techniques. The genomic analysis by witch 
hepatoma Huh7 cells were transducer with lentivirus encoding a hairpin to 
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produce iRNA targeting human Vitamin D Receptor (VDR) had less EEfs than 
the cells transduced with a lentivirus without any hairpin. However, it was 
impossible to correlate the level of VDR knock down with this decrease of in the 
number of EEFs.  
To successfully infect a liver cell Plasmodium migrates trough several 
hepatocytes and then invades a final hepatocyte were it develops in thousands 
of merozoites 69. Our results, that can be considered as preliminary, show that 
the active form of the vitamin D may have a detrimental effect in the invasion or 
development of P. berghei of hepatocytes. More controlled experiments should 
be made, particularly the effect of the drug directly in the parasite and in the 
development of the EEFs inside the hepatocytes. 
 
 4.1.2. In vivo P. berghei infection 
 
In vivo, both small doses of 1,25α(OH)D3 given in small periods of time 
and higher doses given for larger periods had no effect in P. berghei liver 
infection. A tendency in the results could be observed were small doses of 
1,25α(OH)D3 administered in a short period of time reduced the number of P. 
berghei DNA copies, in mice livers whether bigger amounts administered for 
longer was found a tendency for an increased of P. berghei DNA copies 
compared with controls. Also, mice treated with higher amounts of 1,25α(OH)D3 
had higher expression VDR and this expression was significantly correlated with 
higher copies of P. berghei in the mice livers. This has been already described 
for Toxoplasma gondii in which 1,25α-(OH)D3 enhanced mice susceptibility to 
toxoplasmosis, however reducing it’s development 80. A host inflammatory 
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response seems to be detrimental to Plasmodium liver infection 93,27. Hosts 
models with less pronounced inflammatory responses are more susceptible to 
liver infection and induction of liver inflammatory response by P. berghei 
reduces liver greatly reduces P. yoelii liver infection. The anti-inflammatory 
effect that 1,25α(OH)D3 induces may be promoting P. berghei invasion and/or 
development.  
To clearly define in vivo relationship between Vitamin D and P. berghei 
liver infection a better experimental design should be used, such as comparing 
P.berghei liver infection in both mice fed in depleted and complete vitamin D 
and also quantifying circulating titters of vitamin D forms. 
 
4.2. Blood stage infection 
 
Understanding the pathogenesis of malaria infection is crucial for the 
development of more efficient clinical interventions. Sequestration of infected 
erythrocytes and leukocytes and the inflammatory response triggered by 
malaria infection are thought  two key events in the pathogenesis of cerebral 
malaria 14. 
From the Vial and co-workers report  1,25α(OH)D3 was an “effective 
inhibitor of the in vitro intraerythrocytic growth of Plasmodium falciparum” they 
showed that this drug had schizonticidal action 95. When we proposed this 
study, we were expecting some effect of 1,25α(OH)D3 on peripheral blood 
parasitemias in vivo. In this work, was not possible to test the effect of 
1,25α(OH)D3 in in vitro P. berghei blood cultures, it would be very interesting to 
test this hypothesis. 
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Vitamin D has been suggested to affect the balance between T helper 
Th1 and Th2 type cytokines by favouring Th2 domination 48.This inhibition of 
pro-inflammatory and boost of anti-inflammatory make as think that 
1,25α(OH)D3 would have a beneficial effect in the outcome of experimental 
cerebral malaria. Our results don’t show differences between the different doses 
of 1,25α-(OH)D3 or between different routes of administration both in 
parasitemia nor in CM incidence, all mice died in the cerebral malaria window 
and with similar parasitemias. 
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5. Conclusions 
 
The results presented in this work suggest that vitamin D, particularly its 
active form 1,25α(OH)D3, may have some influence in the liver phase infection 
of Plasmodium Berghei. More controlled experiments and bigger sample size, 
specially in vivo, may elucidate the existence or not of a Vitamin D Receptor-
vitamin D influence in P. berghei hepatocytes infection. 1,25α(OH)D3 did not 
affected the parasitemias nor the outcome  of cerebral malaria suggesting that 
vitamin D supplementation has no effect on P. berghei blood stage infection. 
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